We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top
Read MoreHide Full Article
Arena Pharmaceuticals, Inc. incurred loss of $1.76 per share for the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of $1.62. The company had recorded earnings of $1.35 in the year-ago quarter.
Moreover, Arena’s total revenues of $3 million in the reported quarter plunged 65.3% year over year. However, the top line beat the Zacks Consensus Estimate of $1.06 million.
Shares of Arena were up 4.5% in after-market trading on Feb 26, following the earnings release. However, the company’s stock has declined 4.8% in the past year compared with the industry’s decrease of 9.2%.
Quarterly Details
Arena recorded collaboration and other revenues of $6.6 million, down 4.3% year over year, which included $5 million development milestone revenues from its collaboration partner, Everest Medicines, in Greater China. The partner initiated a phase III study to evaluate Arena’s pipeline candidate, etrasimod, in patients with ulcerative colitis (“UC”) in October 2019.
The company recorded royalty revenues of negative $3.6 million due to reduction in estimated future royalties from Belviq sales. It has a collaboration agreement with Japan-based Eisai for commercialization of the weight management drug. Earlier this month, Eisai announced voluntary withdrawal of Belviq from the U.S. market following FDA’s recommendation. The FDA reviewed data from a cardiovascular outcomes study evaluating Belviq and assessed that the drug has an unfavorable risk-benefit profile. Data showed that patients treated with Belviq and diagnosed with cancer were higher than placebo.
Research & development (R&D) expenses escalated 96.8% from the prior-year level to $74.6 million.
General and administrative (G&A) expenses surged 72% to $22.2 million from the year-ago figure.
The company ended the year with $1.1 billion in cash, cash equivalents and investments. It is anticipating net cash used in the first quarter of 2020 to be approximately $95 million and increase in high single digits to low double digits every quarter in the year.
Full Year Results
Arena reported total revenues of $806.4 million in 2019, compared with $18 million in 2018. The significant increase was due to $800 million in upfront payment received from United Therapeutics (UTHR - Free Report) in 2019 related to license agreement for Arena’s pulmonary arterial hypertension candidate, ralinepag.
The company’s earnings were $7.69 per share in 2019. In the year-ago period, it had incurred a loss of 63 cents per share.
Pipeline Update
Arena’s pipeline currently consists of two key candidates, namely etrasimod and olorinab.
Etrasimod is presently in late-stage development for UC. Arena is currently enrolling patients in a pivotal phase III ELEVATE UC 52 study evaluating etrasimod for treating moderately-to-severely active UC.
The study is part of the ELEVATE UC registrational program, which comprises two pivotal studies to evaluate etrasimod in UC patients. The company has plans to initiate ELEVATE UC 12, a 12-week induction study, later this year.
A phase IIb study — ADVISE — is evaluating etrasimod in patients with atopic dermatitis. Data from the study is expected in the second half of 2020. Another phase IIb study — CULTIVATE — was initiated earlier this year to evaluate the candidate in Crohn's disease.
Two separate mid-stage studies are planned for initiation later this year to evaluate etrasimod in patients with eosinophilic esophagitis, a gastro-intestinal disease, or alopecia areata, an autoimmune disorder.
A phase II CAPTIVATE study is evaluating another candidate, olonarib, as a treatment for abdominal pain associated with irritable bowel syndrome. Data from the study is expected in the second half of 2020. The company also has an early-stage candidate, APD418, for treating acute heart failure. The candidate was granted Fast Track designation for the indication by the FDA last month.
In January 2020, Arena announced that it will form a new subsidiary, Arena Neuroscience. The subsidiary will focus on programs and platforms to develop therapies targeting neuroinflammation indications.
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Vertex’s earnings per share estimates have moved up from $6.68 to $7.57 for 2020 and from $8.59 to $9.62 for 2021 in the past 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 21.76%. Share price of the company has increased 22.3% in the past year.
Loss estimates for Clovis narrowed from $4.78 to $4.73 for 2020 and from $3.38 to $3.33 for 2021 in the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
Image: Bigstock
Arena Pharmaceuticals (ARNA) Q4 Earnings Miss, Revenues Top
Arena Pharmaceuticals, Inc. incurred loss of $1.76 per share for the fourth quarter of 2019, wider than the Zacks Consensus Estimate of a loss of $1.62. The company had recorded earnings of $1.35 in the year-ago quarter.
Moreover, Arena’s total revenues of $3 million in the reported quarter plunged 65.3% year over year. However, the top line beat the Zacks Consensus Estimate of $1.06 million.
Shares of Arena were up 4.5% in after-market trading on Feb 26, following the earnings release. However, the company’s stock has declined 4.8% in the past year compared with the industry’s decrease of 9.2%.
Quarterly Details
Arena recorded collaboration and other revenues of $6.6 million, down 4.3% year over year, which included $5 million development milestone revenues from its collaboration partner, Everest Medicines, in Greater China. The partner initiated a phase III study to evaluate Arena’s pipeline candidate, etrasimod, in patients with ulcerative colitis (“UC”) in October 2019.
The company recorded royalty revenues of negative $3.6 million due to reduction in estimated future royalties from Belviq sales. It has a collaboration agreement with Japan-based Eisai for commercialization of the weight management drug. Earlier this month, Eisai announced voluntary withdrawal of Belviq from the U.S. market following FDA’s recommendation. The FDA reviewed data from a cardiovascular outcomes study evaluating Belviq and assessed that the drug has an unfavorable risk-benefit profile. Data showed that patients treated with Belviq and diagnosed with cancer were higher than placebo.
Research & development (R&D) expenses escalated 96.8% from the prior-year level to $74.6 million.
General and administrative (G&A) expenses surged 72% to $22.2 million from the year-ago figure.
The company ended the year with $1.1 billion in cash, cash equivalents and investments. It is anticipating net cash used in the first quarter of 2020 to be approximately $95 million and increase in high single digits to low double digits every quarter in the year.
Full Year Results
Arena reported total revenues of $806.4 million in 2019, compared with $18 million in 2018. The significant increase was due to $800 million in upfront payment received from United Therapeutics (UTHR - Free Report) in 2019 related to license agreement for Arena’s pulmonary arterial hypertension candidate, ralinepag.
The company’s earnings were $7.69 per share in 2019. In the year-ago period, it had incurred a loss of 63 cents per share.
Pipeline Update
Arena’s pipeline currently consists of two key candidates, namely etrasimod and olorinab.
Etrasimod is presently in late-stage development for UC. Arena is currently enrolling patients in a pivotal phase III ELEVATE UC 52 study evaluating etrasimod for treating moderately-to-severely active UC.
The study is part of the ELEVATE UC registrational program, which comprises two pivotal studies to evaluate etrasimod in UC patients. The company has plans to initiate ELEVATE UC 12, a 12-week induction study, later this year.
A phase IIb study — ADVISE — is evaluating etrasimod in patients with atopic dermatitis. Data from the study is expected in the second half of 2020. Another phase IIb study — CULTIVATE — was initiated earlier this year to evaluate the candidate in Crohn's disease.
Two separate mid-stage studies are planned for initiation later this year to evaluate etrasimod in patients with eosinophilic esophagitis, a gastro-intestinal disease, or alopecia areata, an autoimmune disorder.
A phase II CAPTIVATE study is evaluating another candidate, olonarib, as a treatment for abdominal pain associated with irritable bowel syndrome. Data from the study is expected in the second half of 2020. The company also has an early-stage candidate, APD418, for treating acute heart failure. The candidate was granted Fast Track designation for the indication by the FDA last month.
In January 2020, Arena announced that it will form a new subsidiary, Arena Neuroscience. The subsidiary will focus on programs and platforms to develop therapies targeting neuroinflammation indications.
Arena Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Arena Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Arena Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Arena currently carries a Zacks Rank #3 (Hold).
A couple of better-ranked stocks in the biotech sector are Vertex Pharmaceuticals Incorporated (VRTX - Free Report) and Clovis Oncology . Both stocks carry a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Vertex’s earnings per share estimates have moved up from $6.68 to $7.57 for 2020 and from $8.59 to $9.62 for 2021 in the past 30 days. The company delivered a positive earnings surprise in all the trailing four quarters, with the average being 21.76%. Share price of the company has increased 22.3% in the past year.
Loss estimates for Clovis narrowed from $4.78 to $4.73 for 2020 and from $3.38 to $3.33 for 2021 in the past 30 days.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.
This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.
See their latest picks free >>